Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PFO closure vs medicine for migraine (SPRING)
NCT04946734Phase 3Active, not recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Aug 2021
- Primary completion
- Sep 2025
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in migraine, sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Complete cessation of migraine at 12 months and Serious Adverse Event at 12 months. Started Aug 2021; status: active, not recruiting.
02
Conditions
migraine
Beyond the preview
Go deeper on NCT04946734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04946734.